Literature DB >> 23628738

Opinion: A role for placebo therapy in psychogenic movement disorders.

Karen S Rommelfanger1.   

Abstract

Psychogenic movement disorders (PMDs) mimic known movement disorders but are not attributed to an underlying neurological pathology and are generally thought to have a psychological origin. Owing to the lack of a clear pathology, patients often experience multiple referrals, frequent office visits, and numerous--often fruitless--technically sophisticated tests and interventions. No standard of care exists for PMDs, and affected patients can experience debilitating symptoms for a lifetime. Some physicians advocate the use of placebo treatment for patients with PMDs, and placebo therapy can have beneficial neurophysiological effects. Innovative research will be necessary to develop effective therapeutics for psychogenic disorders and to make recommendations for future clinician training and health care policy. This Perspectives article aims to trigger international dialogue focusing on the diagnosis and treatment of patients with PMDs, and to reframe and deepen discussion of placebo prescribing for PMDs and beyond.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23628738     DOI: 10.1038/nrneurol.2013.65

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN: 1759-4758            Impact factor:   42.937


  47 in total

Review 1.  Functional (psychogenic) movement disorders.

Authors:  Kathrin Czarnecki; Mark Hallett
Journal:  Curr Opin Neurol       Date:  2012-08       Impact factor: 5.710

2.  Psychogenic tremor: long-term outcome.

Authors:  Joseph Jankovic; Kevin Dat Vuong; Madhavi Thomas
Journal:  CNS Spectr       Date:  2006-07       Impact factor: 3.790

3.  Psychogenic movement disorders and motor conversion: a roadmap for collaboration between neurology and psychiatry.

Authors:  Sarah M Kranick; Tristan Gorrindo; Mark Hallett
Journal:  Psychosomatics       Date:  2011 Mar-Apr       Impact factor: 2.386

4.  Effects of expectation on placebo-induced dopamine release in Parkinson disease.

Authors:  Sarah C Lidstone; Michael Schulzer; Katherine Dinelle; Edwin Mak; Vesna Sossi; Thomas J Ruth; Raul de la Fuente-Fernández; Anthony G Phillips; A Jon Stoessl
Journal:  Arch Gen Psychiatry       Date:  2010-08

5.  Psychogenic nonepileptic seizures in US veterans.

Authors:  Martin Salinsky; David Spencer; Eilis Boudreau; Felicia Ferguson
Journal:  Neurology       Date:  2011-09-06       Impact factor: 9.910

6.  The treatment of psychogenic movement disorders with suggestion is ethically justified.

Authors:  Michel C F Shamy
Journal:  Mov Disord       Date:  2010-02-15       Impact factor: 10.338

7.  Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions.

Authors:  Christopher G Goetz; Joanne Wuu; Michael P McDermott; Charles H Adler; Stanley Fahn; Curt R Freed; Robert A Hauser; Warren C Olanow; Ira Shoulson; P K Tandon; Sue Leurgans
Journal:  Mov Disord       Date:  2008-04-15       Impact factor: 10.338

Review 8.  The placebo treatments in neurosciences: New insights from clinical and neuroimaging studies.

Authors:  Nico J Diederich; Christopher G Goetz
Journal:  Neurology       Date:  2008-08-26       Impact factor: 9.910

Review 9.  Psychogenic movement disorders.

Authors:  Amitabh Gupta; Anthony E Lang
Journal:  Curr Opin Neurol       Date:  2009-08       Impact factor: 5.710

10.  Psychogenic movement disorders: frequency, clinical profile, and characteristics.

Authors:  S A Factor; G D Podskalny; E S Molho
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-10       Impact factor: 10.154

View more
  8 in total

1.  Treatment of functional motor disorders.

Authors:  Jeannette M Gelauff; Yasmine E M Dreissen; Marina A J Tijssen; Jon Stone
Journal:  Curr Treat Options Neurol       Date:  2014-04       Impact factor: 3.598

Review 2.  Functional neurological disorder and placebo and nocebo effects: shared mechanisms.

Authors:  Mark J Edwards; Michele Tinazzi; Mirta Fiorio; Miriam Braga; Angela Marotta; Bernardo Villa-Sánchez; Diletta Barbiani
Journal:  Nat Rev Neurol       Date:  2022-09-08       Impact factor: 44.711

Review 3.  The Phenomenology of Functional (Psychogenic) Dystonia.

Authors:  Christos Ganos; Mark J Edwards; Kailash P Bhatia
Journal:  Mov Disord Clin Pract       Date:  2014-04-10

Review 4.  Functional Movement Disorders and Placebo: A Brief Review of the Placebo Effect in Movement Disorders and Ethical Considerations for Placebo Therapy.

Authors:  Bonnie M Kaas; Casey Jo Humbyrd; Alexander Pantelyat
Journal:  Mov Disord Clin Pract       Date:  2018-10-09

5.  Recognizing uncommon presentations of psychogenic (functional) movement disorders.

Authors:  José Fidel Baizabal-Carvallo; Robert Fekete
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2015-01-21

Review 6.  Placebos as a Source of Agency: Evidence and Implications.

Authors:  Phoebe Friesen
Journal:  Front Psychiatry       Date:  2019-10-25       Impact factor: 4.157

7.  Suggestibility as a valuable criterion for laboratory-supported definite functional movement disorders.

Authors:  Gerard Saranza; Daniel Vargas-Mendez; Anthony E Lang; Robert Chen
Journal:  Clin Neurophysiol Pract       Date:  2021-03-17

8.  Expectancy in placebo-controlled trials of psychedelics: if so, so what?

Authors:  Matt Butler; Luke Jelen; James Rucker
Journal:  Psychopharmacology (Berl)       Date:  2022-09-05       Impact factor: 4.415

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.